No benefit from continued use of AstraZeneca's Iressa drug
September 28, 2014 at 02:59 AM EDT
MADRID, Sept 28 (Reuters) - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit.
